Predictmedix Announces
Production of AI-Powered Mobile Application to Detect Impairment
from Alcohol and Cannabis
-
Predictmedix
has begun production of its mobile application for detecting
impairment from cannabis and alcohol
-
Predictmedix's
screening to identify impairment takes less than 30
seconds
-
The mobile
application, powered by AI algorithms currently being utilized in
Safe Entry will be accompanied by a "mini" multi-spectral imaging
camera resulting in a portable non-invasive impairment detection
solution
-
Commercialization will specifically target Law Enforcement,
Transport, and other mobile high-risk industries
Toronto, Ontario,
March 15, 2023 -- InvestorsHub NewsWire -- Predictmedix Inc.
("Predictmedix" or the "Company") (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP), an emerging provider of rapid
health screening solutions powered by a proprietary artificial
intelligence (AI), today announced the production of its AI-Powered
mobile app in conjunction with a portable multi-spectral imaging
camera to non-invasively detect impairment from alcohol and
cannabis. The non-invasive solution will be commercialized with the
intent to serve global law enforcement agencies, transport, and
other mobile high-risk industries where impairment remains a
significant liability. Additionally, the Company has achieved an
accuracy of over 90% in identifying impaired individuals in the
recently conducted study with the screening time being below 30
seconds to identify impairment. Although, cannabis breathalyzers
are still at an early stage of development, alcohol breathalyzers
have been reported to have upto a 50% margin of error according to
the National Motorists Association1.
Impairment from
alcohol and cannabis has been an ongoing issue for law enforcement
and high-risk industries around the world – and current testing
protocols are long, costly, and onerous. Drug testing companies
have failed to create a product that is reliable, quick,
cost-effective, and non-invasive all in one product. Predictmedix's
portable solution intended for law enforcement agencies and other
high-risk mobile industries addresses the problems that companies
and organizations have been facing for many years.
A
multiparametric approach is used to identify unique and specific
features based on facial and speech analysis which are analyzed by
AI algorithms, resulting in an un-biased outcome. The
multi-spectral imaging camera captures non-visible wavelength data
which the AI algorithms extract features that are associated with
impairment from alcohol and/or cannabis. AI by nature is
self-learning, Predictmedix's algorithms improve as more data is
obtained and processed resulting in greater accuracy and speed with
time.
Although the
combination of both multispectral imaging and speech analysis has
resulted in an accuracy of over 90% to identify impaired
individuals, the Speech Analysis component of the solution by
itself has achieved an impressive accuracy rate in identifying
impairment. Predictmedix is cognizant of the potential this
specific use-case has for the end consumer and is currently taking
action to preserve the rights and IP of the technology for
commercialization efforts and shareholder concerns.
"We are happy to
announce to our shareholders that we are making very good progress
with our portable solution for detecting impairment in individuals.
From our research and discussions with high-level contacts, we
believe our product will be in high demand in multiple industry
verticals worldwide. In 2021, the drug screening market size was
valued at over $5.2 Billion with revenue forecasted at over $22
Billion in 20302,
making this another lucrative opportunity for Predictmedix,"
commented Dr. Rahul Kushwah, Chief Operating Officer at
Predictmedix. "We look forward to updating our shareholders on
further technological and commercial development."
1 https://ww2.motorists.org/issues/dui/breathalyzers-fail-legitimacy-test/
2
https://www.emergenresearch.com/industry-report/drug-screening-market
About Predictmedix
Inc.
Predictmedix (CSE:
PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid
health screening and remote patient care solutions globally. The
Company's Safe Entry Stations – powered by a proprietary artificial
intelligence (AI) – use multispectral cameras to analyze
physiological data patterns and predict a variety of health issues
including infectious diseases such as COVID-19, impairment by drugs
or alcohol, fatigue or various mental illnesses. Predictmedix's
proprietary remote patient care platform empowers medical
professionals with a suite of AI-powered tools to improve patient
health outcomes. To learn more, please visit our website at
www.Predictmedix.com or follow us on Twitter, Instagram or
LinkedIn.
Public Relations
Contact
For further media
information or to set up an interview, please contact:
Nelson
Hudes
Hudes Communications
International
(905) 660
9155
Nelson@hudescommunications.com
Dr. Rahul
Kushwah
(647) 889
6916
Caution Regarding
Forward-Looking Information:
This news release may
contain forward-looking statements and information based on current
expectations. These statements should not be read as guarantees of
future performance or results of the Company. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management's reasonable
assumptions, there can be no assurance that such assumptions will
prove to be correct. We assume no responsibility to update or
revise them to reflect new events or circumstances. The Company's
securities have not been registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or applicable
state securities laws, and may not be offered or sold to, or for
the account or benefit of, persons in the United States or "U.S.
Persons", as such term is defined in Regulations under the U.S.
Securities Act, absent registration or an applicable exemption from
such registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in the United States
or any jurisdiction in which such offer, solicitation or sale would
be unlawful. Additionally, there are known and unknown risk factors
which could cause the Company's actual results, performance or
achievements to be materially different from any Page 4 of 4 future
results, performance or achievements expressed or implied by the
forward-looking information contained herein, such as, but not
limited to dependence on obtaining regulatory approvals; the
ability to obtain intellectual property rights related to its
technology; limited operating history; general business, economic,
competitive, political, regulatory and social uncertainties, and in
particular, uncertainties related to COVID-19; risks related to
factors beyond the control of the Company, including risks related
to COVID-19; risks related to the Company's shares, including price
volatility due to events that may or may not be within such party's
control; reliance on management; and the emergency of additional
competitors in the industry.
All forward-looking
information herein is qualified in its entirety by this cautionary
statement, and the Company disclaims any obligation to revise or
update any such forward-looking information or to publicly announce
the result of any revisions to any of the forward-looking
information contained herein to reflect future results, events or
developments, except required by law.
Disclaimer: "The
Company is not making any express or implied claims that its
product has the ability to diagnose, eliminate, cure or contain the
COVID-19 (or SARS-2 Coronavirus) at this time."
THE CANADIAN
SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.
